Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice). The most common symptom of infestation is pruritus (itching) on the head which normally intensifies 3 to 4 weeks after the initial infestation.
The test items have been developed with the ambition to offer a complete head lice treatment, whilst also offering ultimative convenience in use - making treatment of head lice infestation easy, and effective in few minutes.
The main objective of this clinical study is to confirm the efficacy on head lice treatment of two Medical Devices, already in market.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Investigational Device | Experimental | Medical device for the treatment of head lice infestation: Paranix® Shampoo, already in the market in Europe Single topical application administered to hair and scalp for 10 minutes. Applied by principal investigator on site. |
|
| Comparator Device | Active Comparator | Medical device for the treatment of head lice infestation: Paranix® Lotion, already in the market in Europe Single topical application administered to hair and scalp for 10 minutes. Applied by principal investigator on site. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Paranix® Shampoo | Device | well established medical device for the treatment of head lice infestation (osmolone based) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy based on the cure rate after complete treatment | The cure rate is defined as the rate of subjects having no live lice on hair 7 days after the last application of the product (Day 7 or Day 14 if second application is needed). | Day 7, Day 14 if applicable |
| Measure | Description | Time Frame |
|---|---|---|
| Cure rate of each individual investigational device | Evaluate the cure rate of each individual investigational device | Day 7, Day 14 |
| Cure rate after one dose of investigational device application |
Not provided
Inclusion Criteria:
Exclusion Criteria:
In terms of associated pathology
Relating to previous or ongoing treatment
Subject undergoing a topical treatment on the test area or a systemic treatment with:
Subject who received an anti-lice treatment in the previous 2 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Manon Laune | Contact | +33 (0)4 72 82 36 56 4409 | mla@dermscan.com |
| Name | Affiliation | Role |
|---|---|---|
| Aslham Doarika, PhD | Insight Collective | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Insight Research | Recruiting | Quatre Bornes | Mauritius |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Paranix® Lotion | Device | well established medical device for the treatment of head lice infestation (dimethicone based) |
|
Comparison of the percentage of subjects cured after one dose of the investigational device compared to the percentage of subjects cured with one dose of the comparator device.
| Day 7 |
| Dead and live lice/nymphs after combing | Number of dead and live lice/nymphs collected on the anti-lice comb after treatment. | Day 0, Day 7 if applicable |
| Live lice and nymphs after application | Evaluation of the presence of live lice and nymphs, for both groups, without combing on hair and close to scalp | Day 1, Day 7, Day 8 if applicable, Day 14 if applicable |
| Number of participants with treatment-related adverse events, serious adverse events as assessed by investigator | Evaluation of the safety and tolerability of the investigational device versus comparator | Day 0, Day 1, Day 7, Day 8 if applicable, and Day 14 if applicable |
| Subject reported perceived acceptability, efficacy and subjective evaluation assessed via questionnaire | Evaluation of the perceived acceptability, subjective efficacy and risk of re-infestation; Subject perception questionnaire with the following scale items: totally agree, agree, rather disagree, disagree | Day 1, Day 7 or Day 14 if applicable |